Rapport Therapeutics, Inc.(RAPP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RAPP Rapport Therapeutics, Inc.

Closed 04-01 16:00:00 EDT

9.56

-0.47

-4.69%

盘后9.56

+0.000.00%

16:05 EDT

High9.94	Low9.25	Vol159.35K
Open9.94	D1 Closing10.03	Amplitude6.88%
Mkt Cap348.91M	Tradable Cap140.93M	Total Shares36.50M
T/O1.52M	T/O Rate1.08%	Tradable Shares14.74M
P/B1.14	ROE-35.09%	EPS-3.78
52wk High29.74	52wk Low6.43	P/E-2.53
Dividend0.00	Div.Yield0.00	ROA-22.07%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":9.56,"timestamp":1743537600000,"preClose":10.03,"halted":0,"volume":159354,"hourTrading":{"tag":"盘后","latestPrice":9.56,"preClose":9.56,"latestTime":"16:05 EDT","volume":1499,"amount":14330.44,"timestamp":1743537910016},"delay":0,"floatShares":14741761,"shares":36496437,"eps":-3.775953,"marketStatus":"Closed","change":-0.47,"latestTime":"04-01 16:00:00 EDT","open":9.94,"high":9.94,"low":9.25,"amount":1523127.475728,"amplitude":0.068794,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.775953,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743580800000},"marketStatusCode":5,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":10.03,"preHourTrading":{"tag":"盘前","latestPrice":10.5,"preClose":10.03,"latestTime":"09:13 EDT","volume":519,"amount":5210.270064,"timestamp":1743513185108},"postHourTrading":{"tag":"盘后","latestPrice":9.56,"preClose":9.56,"latestTime":"16:05 EDT","volume":1499,"amount":14330.44,"timestamp":1743537910016},"volumeRatio":0.915894,"impliedVol":1.0085,"impliedVolPercentile":0.8523},"requestUrl":"/m/hq/s/RAPP/tweets","defaultTab":"tweets","newsList":[{"id":"2521462404","title":"Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521462404","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521462404?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 19:00","pubTimestamp":1742554800,"startTime":"0","endTime":"0","summary":"BOSTON and SAN DIEGO, March 21, 2025  -- Rapport Therapeutics, Inc.  , a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology  Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society  Annual Meeting in December 2024.The presentations will highlight the company’s ongoing research and development of RAP-219, a clinical-stage AMPA receptor  negative allosteric modulator  currently in Phase 2 development for the treatment of refractory focal epilepsy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rapport-therapeutics-present-data-2025-110000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4105","LU1093756325.SGD","BK4588","IE0002270589.USD","AES","IE00B19Z3581.USD","BK4107","BK4519","LENZ","AAN","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4178","LU1093756168.USD","BK4117","LU0061475181.USD","BK4585","AFG","BK4139","RAPP"],"gpt_icon":0},{"id":"2519031674","title":"Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2519031674","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519031674?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 20:17","pubTimestamp":1742041039,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Rapport Therapeutics, Inc.  should definitely note that the Chief Financial Officer, Troy Ignelzi, recently paid US$10.10 per share to buy US$101k worth of the stock. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.Check out our latest analysis for Rapport Therapeutics. The Last 12 Months Of Insider Transactions At Rapport Therapeutics. Notably, that recent purchase by Troy Ignelzi is the biggest insider purchase of Rapport Therapeutics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$10.51. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Rapport Thera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-buying-rapport-therapeutics-chief-121719923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","RAPP","LENZ"],"gpt_icon":0},{"id":"2519987815","title":"Top Executives Make Bold Moves with Major Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2519987815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519987815?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 10:09","pubTimestamp":1741918147,"startTime":"0","endTime":"0","summary":"New insider activity at Rapport Therapeutics, Inc. ( ($RAPP) ) has taken place on March 14, 2025. In recent transactions involving Rapport Therapeu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-major-stock-purchases-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-major-stock-purchases-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2518803984","title":"Rapport Therapeutics Reports 2024 Financial Results and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2518803984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518803984?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 12:14","pubTimestamp":1741752886,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has released its Q4 earnings. Here is a breakdown of the information Rapport Therapeutics, Inc. presented to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2065732104.USD","PRGS","RAPP","BK4097","BK4007","LENZ"],"gpt_icon":0},{"id":"2518125097","title":"Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the year with $305.3M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2518125097","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518125097?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:10","pubTimestamp":1741691409,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.62) by 8.06 percent. This is a 92.88 percent increase over losses of $(8.01) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44242996/rapport-therapeutics-q4-2024-gaap-eps-0-57-beats-0-62-estimate-ended-the-year-with-305-3m-in-cash-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2516605335","title":"Rapport Therapeutics Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2516605335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516605335?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 23:30","pubTimestamp":1741102252,"startTime":"0","endTime":"0","summary":"10:29 EST Rapport Therapeutics (RAPP) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2516058046","title":"Rapport Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2516058046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516058046?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 23:25","pubTimestamp":1741101957,"startTime":"0","endTime":"0","summary":"10:24 EST Rapport Therapeutics (RAPP) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","RAPP"],"gpt_icon":0},{"id":"2516638005","title":"Rapport Therapeutics Appoints New CMO Amid Phase 2a Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516638005","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516638005?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:49","pubTimestamp":1741006147,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has shared an announcement. On March 3, 2025, Rapport Therapeutics announced the appointment of Jeffrey Sevi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-appoints-new-cmo-amid-phase-2a-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-appoints-new-cmo-amid-phase-2a-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2516680974","title":"Rapport Therapeutics : Intends to Initiate Additional Phase 2a Trial of Rap-219 in Bipolar Mania in Q3 2025 With Topline Data Expected in H1 of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680974?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:17","pubTimestamp":1741004244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2516994687","title":"Rapport Therapeutics Announces Appointment of DR. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2516994687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516994687?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:00","pubTimestamp":1741003202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA8F5FSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2516687647","title":"Press Release: Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687647","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687647?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development. In his role as CMO, Dr. Sevigny will oversee the development and execution of Rapport's clinical strategy and will be responsible for ensuring the advancement of Rapport's pipeline of precision medicines leveraging receptor associated protein  science. Building on the momentum of Rapport's RAP-219 program, his proven ability to advance clinical programs through late-stage clinical trials and regulatory approval will be instrumental in progressing RAP-219 and the broader pipeline.\"We are thrilled to welcome Jeff to Rapport. His extensive experience leading successful clinical development programs and driving drug development in neuroscience make him the ideal addition to our executive team and leader of our clinical development capability,\" said Abraham N. Ceesay, chief executive officer of Rapport. \"Jeff's proven ability in building e","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4600","BK4585","LENZ","RAPP","BK4516","BK4007","BK4595","BK4588","BK4139","BK4135","CNS","BK4023","BK4596","STRK"],"gpt_icon":1},{"id":"2513401157","title":"Rapport Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513401157","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513401157?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 20:00","pubTimestamp":1740398400,"startTime":"0","endTime":"0","summary":"BOSTON and SAN DIEGO, Feb. 24, 2025  -- Rapport Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system  disorders, today announced that management will present at two upcoming investor conferences in March 2025.TD Cowen 45th Annual Health Care Conference  – fireside chat on Tuesday, March 4, 2025, at 3:10-3:40pm EST.Stifel 2025 Virtual CNS Forum – fireside chat on Wednesday, March 19, 2025, at 10:30-10:55am EST.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rapport-therapeutics-participate-upcoming-investor-120000075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4139","RAPP","LENZ","BK4007","CNS"],"gpt_icon":0},{"id":"2510825711","title":"Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2510825711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510825711?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 12:27","pubTimestamp":1739248045,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday and set a price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4127","RAPP","BK4007"],"gpt_icon":0},{"id":"2502862363","title":"Promising Clinical Trial Results and Stable Leadership Secure Buy Rating for Rapport Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2502862363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502862363?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 22:16","pubTimestamp":1736518568,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh has reiterated their bullish stance on RAPP stock, giving a Buy rating today. Justin Walsh has given his Buy rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-trial-results-and-stable-leadership-secure-buy-rating-for-rapport-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-trial-results-and-stable-leadership-secure-buy-rating-for-rapport-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2502613855","title":"Stifel Nicolaus Remains a Buy on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502613855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502613855?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 18:47","pubTimestamp":1736506028,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4007","RAPP","BK4127"],"gpt_icon":0},{"id":"2502988044","title":"Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2502988044","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502988044?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 00:44","pubTimestamp":1736441063,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics  said Thursday that preliminary analysis of data from positron emission tomography and the second multiple ascending dose trials for RAP-219 showed it achieved target receptor occupancy within five days of dosing.The investigational drug also maintained a differentiated tolerability profile, according to the company.The company is evaluating RAP-219 in patients with refractory focal epilepsy in a phase 2a proof-of-concept trial and expects topline results in mid-2025.Price: 16.69, Change: -1.10, Percent Change: -6.16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2502011580","title":"Rapport Therapeutics announces new Phase 1 data for RAP-219","url":"https://stock-news.laohu8.com/highlight/detail?id=2502011580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502011580?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 20:20","pubTimestamp":1736425214,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) announced results from its positron emission tomography trial and second multiple ascending dose trial for RAP-219. Dat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-announces-new-phase-1-data-for-rap-219?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-announces-new-phase-1-data-for-rap-219?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2502361015","title":"Rapport Therapeutics Inc - Phase 2a Trial of Rap-219 on Track, Data Expected Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502361015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502361015?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nTUA6FRQX5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2502153950","title":"Rapport Therapeutics Announces New Phase 1 Data, Further Supporting Rap-219'S Transformative Potential for CNS Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2502153950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502153950?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nTUA6FRQX5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2502015616","title":"Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2502015616","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502015616?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":"In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3006949/0/en/Rapport-Therapeutics-Announces-New-Phase-1-Data-Further-Supporting-RAP-219-s-Transformative-Potential-for-CNS-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4181","BK4218","CNS","RAPP","BK4135","PET","BK4192","ECG","BK4129","BK4007","PK","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rapportrx.com","stockEarnings":[{"period":"1week","weight":-0.0186},{"period":"1month","weight":0},{"period":"3month","weight":-0.4346},{"period":"6month","weight":-0.4622},{"period":"1year","weight":-0.41},{"period":"ytd","weight":-0.4346}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0586},{"period":"3month","weight":-0.0455},{"period":"6month","weight":-0.0166},{"period":"1year","weight":0.0694},{"period":"ytd","weight":-0.0455}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Rapport Therapeutics, Inc.","nameEN":"Rapport Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rapport Therapeutics, Inc.(RAPP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rapport Therapeutics, Inc.(RAPP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rapport Therapeutics, Inc.,RAPP,Rapport Therapeutics, Inc.股票,Rapport Therapeutics, Inc.股票老虎,Rapport Therapeutics, Inc.股票老虎国际,Rapport Therapeutics, Inc.行情,Rapport Therapeutics, Inc.股票行情,Rapport Therapeutics, Inc.股价,Rapport Therapeutics, Inc.股市,Rapport Therapeutics, Inc.股票价格,Rapport Therapeutics, Inc.股票交易,Rapport Therapeutics, Inc.股票购买,Rapport Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rapport Therapeutics, Inc.(RAPP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rapport Therapeutics, Inc.(RAPP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction